

Dominick J Angiolillo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1653605/dominick-j-angiolillo-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

519
papers

29,525
citations

84
h-index

157
g-index

630
ext. papers

35,972
ext. citations

6.6
avg, IF

7.17
L-index

#	Paper	IF	Citations
519	Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation.. <i>Clinical Pharmacokinetics</i> , 2022 , 61, 465	6.2	1
518	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 282-282	5	0
517	Reply: The Effects of Cangrelor on Platelet Aggregation in STEMI Patients: Methodological or Pharmacological Issues?. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 230-231	5	
516	Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens with COVID-19.. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022 ,	6.4	2
515	ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024156	6	2
514	SCAI Expert Consensus Statement on Sex-Specific Considerations in Myocardial Revascularization 2022 , 100016		1
513	Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024159	6	1
512	Short Duration of DAPT Versus De-Escalation After Percutaneous Coronary Intervention for Acute Coronary Syndromes.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 268-277	5	9
511	Septal perforating artery originating from the ramus intermedius artery. <i>Coronary Artery Disease</i> , 2022 , 31, e13-e14	1.4	
510	Antiplatelet therapy after percutaneous coronary intervention.. <i>EuroIntervention</i> , 2022 , 17, e1371-e1396	3.1	5
509	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.. <i>Circulation: Cardiovascular Interventions</i> , 2022 , CIRCINTERVENTIONS	6	9
508	Reply: Short Duration of DAPT vs De-Escalation After Percutaneous Coronary Intervention: Only These 2 Options?. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 903-904	5	
507	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease 2022 , 407-419		
506	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.. <i>European Heart Journal</i> , 2021 ,	9.5	8
505	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 2060-2072	15.1	2
504	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1550-1563	15.1	2
503	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021 , 144, 1323-1343	16.7	9

502	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1703-1712	27.4	36
501	Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 2410-2412	5	2
500	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, 1111-1119	2.7	1
499	Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial". <i>Circulation</i> , 2021 , 143, e795-e796	16.7	1
498	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 419-428	5.1	0
497	Cilostazol: a Review of Basic Mechanisms and Clinical Uses. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	5
496	Antithrombotic Management of Elderly Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 723-738	5	5
495	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Lancet, The</i> , 2021 , 397, 1470-1483	40	32
494	Aspirin for Primary Prevention of Cardiovascular Disease in the 21 Century: A Review of the Evidence. <i>American Journal of Cardiology</i> , 2021 , 144 Suppl 1, S15-S22	3	6
493	Systematic Assessment of Online Health Information for Coronary Revascularization. <i>JAMA Internal Medicine</i> , 2021 , 181, 1003-1006	11.5	0
492	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021 , 17, 59-66	3.1	6
491	Tackling the gap in platelet inhibition with oral antiplatelet agents in high-risk patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 19, 519-535	2.5	3
490	Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. <i>Current Opinion in Cardiology</i> , 2021 , 36, 390-396	2.1	1
489	Canakinumab for secondary prevention of coronary artery disease. <i>Future Cardiology</i> , 2021 , 17, 427-442	1.3	2
488	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 963-978	3.8	8
487	Efficacy and safety of dual pathway inhibition in patients with cardiovascular disease: a systematic review and Meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	4
486	Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1323-1333	5	0
485	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021 , 373, n1332	5.9	54

484	Ticagrelor or Prasugrel for Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention: A Prespecified Subgroup Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1121-1129	16.2	5
483	Impaired Clinical Efficacy of Aspirin in Hypoalbuminemic Patients With Diabetes Mellitus. <i>Frontiers in Pharmacology</i> , 2021 , 12, 695961	5.6	1
482	Impact Of Chronic Kidney Disease On The Pharmacodynamic And Pharmacokinetic Effects Of Ticagrelor In Patients With Diabetes Mellitus And Coronary Artery Disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	2
481	Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. <i>Journal of the American Heart Association</i> , 2021 , 10, e022125	6	8
480	Methodologic Considerations on Four Cardiovascular Interventions Trials With Contradictory Results. <i>Annals of Thoracic Surgery</i> , 2021 , 111, 690-699	2.7	5
479	Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. <i>Nature Reviews Cardiology</i> , 2021 , 18, 37-57	14.8	9
478	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. <i>American Heart Journal</i> , 2021 , 231, 147-156	4.9	10
477	Safety and efficacy of P2Y inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 9-21	4.1	6
476	Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. <i>Journal of the American Heart Association</i> , 2021 , 10, e019650	6	58
475	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , 2021 , 121, 422-432	7	47
474	Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI. <i>International Journal of Cardiology</i> , 2021 , 328, 40-45	3.2	6
473	MRP4 over-expression has a role on both reducing nitric oxide-dependent antiplatelet effect and enhancing ADP induced platelet activation. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 625-632	5.1	2
472	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021 , 42, 1289-1367	9.5	920
471	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 705-715	6.1	8
470	Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study. <i>BMJ Open Diabetes Research and Care</i> , 2021 , 9,	4.5	3
469	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 444-456	5	3
468	Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 741-747	5.1	0
467	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , 2021 , 143, 583-596	16.7	31

466	Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2021 , 10, e017008	6	6
465	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021 , 42, 2235-2259	9.5	8
464	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1434-1446	5	1
463	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2021 ,	14.8	10
462	Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021 , 17, 443-444	3.1	0
461	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021 , 42, 4683-4693	9.5	5
460	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1688-1703	5	8
459	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	3
458	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021 , 337, 1-8	3.2	2
457	Severe, Intolerable Fatigue Associated with Hyperresponse to Clopidogrel. <i>World Neurosurgery</i> , 2021 , 156, e374-e380	2.1	
456	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1032-1041	16.2	8
455	Rationale and design of the BA-SCAD (Beta-blockers and Antiplatelet agents in patients with Spontaneous Coronary Artery Dissection) randomized clinical trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 ,	0.7	1
454	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	14
453	Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. <i>Minerva Cardiology and Angiology</i> , 2021 , 69, 398-407	2.4	1
452	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1857-1866	5	2
451	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1870-1883	5	14
450	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021 , 42, 4624-4634	9.5	6
449	Platelet physiology and pharmacology—relevant considerations for patient care 2021 , 15-45		

448	The Role of Antiplatelet Therapy in Patients With MINOCA.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 821297	5.4	1
447	Appraising the contemporary role of aspirin for primary and secondary prevention of atherosclerotic cardiovascular events.. <i>Expert Review of Cardiovascular Therapy</i> , 2021 , 1-21	2.5	0
446	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. <i>Journal of the American Heart Association</i> , 2020 , 9, e018897	6	9
445	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2436-2446	15.1	23
444	Ticagrelor or Prasugrel for Platelet Inhibition in Acute Coronary Syndrome Patients: The ISAR-REACT 5 Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2569-2571	15.1	13
443	Selatogrel, a novel P2Y inhibitor: a review of the pharmacology and clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 537-546	5.9	15
442	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing. <i>JACC Basic To Translational Science</i> , 2020 , 5, 419-428	8.7	10
441	Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial. <i>Cardiovascular Research</i> , 2020 , 116, e70-e72	9.9	0
440	Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 874-876	0.7	
439	Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1147-1158	7	13
438	Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 337-343	5.1	7
437	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 578-586	15.1	39
436	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 606-617	5	35
435	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020 , 17, 242-257	14.8	41
434	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. <i>Circulation</i> , 2020 , 141, 891-901	16.7	16
433	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020 , 109, 930-943	6.1	9
432	COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. <i>American Heart Journal</i> , 2020 , 224, 10-16	4.9	7
431	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2403-2413	15.1	34

430	Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2414-2424	15.1	58
429	Fractional Flow Reserve-Based Coronary Artery Bypass Surgery: Current Evidence and Future Directions. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 1086-1096	5	14
428	Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study. <i>Journal of the American Heart Association</i> , 2020 , 9, e015865	6	9
427	Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. <i>Journal of the American Heart Association</i> , 2020 , 9, e014611	6	5
426	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2711-2722	15.1	53
425	Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience. <i>TH Open</i> , 2020 , 4, e437-e445	2.7	6
424	Pooling the Evidence at the Patient Level: End of the Bivalirudin Saga?. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 191-193	7	3
423	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 3132-3140	9.5	24
422	Clinical Utility of Pharmacogene Panel-Based Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical and Translational Science</i> , 2020 , 13, 473-481	4.9	8
421	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 179	8.7	4
420	Timing of Oral P2Y Inhibitor Administration in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2450-2459	15.1	33
419	Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. <i>Circulation</i> , 2020 , 142, 2316-2328	16.7	11
418	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020 , 41, 3533-3545	9.5	37
417	Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS-6 Study. <i>Circulation</i> , 2020 , 142, 1500-1502	16.7	6
416	Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis. <i>JAMA Internal Medicine</i> , 2020 , 180, 1638-1648	11.5	25
415	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 2238-2247	5	11
414	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. <i>Genetics in Medicine</i> , 2020 , 22, 1898-1902	8.1	4
413	An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2020 , 18, 449-464	2.5	3

412	Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. <i>Trials</i> , 2020 , 21, 966	2.8	0
411	Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. <i>Circulation</i> , 2020 , 142, 2172-2188	16.7	12
410	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes : Results From a Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 436-444	8	30
409	Acceso radial frente a femoral y bivalirudina frente a heparina no fraccionada en pacientes vulnerables con síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 874-876	1.5	
408	Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids and crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020	6.4	13
407	Safety and Efficacy of Double Antithrombotic Therapy With Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2020 , 9, e017212	6	24
406	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. <i>American Heart Journal</i> , 2020 , 228, 1-7	4.9	3
405	Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020 , 142, 2329-2337	16.7	14
404	Reply: P2Y Inhibitor-Based Monotherapy: Optimal Duration and Ideal Agent. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1274-1275	15.1	
403	Clopidogrel drug interactions: a review of the evidence and clinical implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 1079-1096	5.5	2
402	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1468-1483	15.1	16
401	Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 83-93	7	14
400	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2019 , 139, 1661-1670	16.7	69
399	Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 554-562	5.1	18
398	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019 , 394, 1169-1180	40	106
397	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019 , 381, 1524-1534	59.2	327
396	Dual antithrombotic therapy for atrial fibrillation and PCI. <i>Lancet, The</i> , 2019 , 394, 1300-1302	40	9
395	Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study. <i>JACC Basic To Translational Science</i> , 2019 , 4, 763-775	8.7	8

394	Reply: Platelet Function and Genetic Testing in Patients Receiving Oral Anticoagulation and Antiplatelet Treatment: An Area of Unmet Need. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1868-1869 ⁵		0
393	Three-Dimensional Echocardiography for Transcatheter Aortic Valve Replacement Sizing: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019 , 8, e013463	6	15
392	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. <i>JAMA Cardiology</i> , 2019 , 4, 1092-1101	16.2	63
391	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019 , 381, 2032-2042	59.2	395
390	Emergency Consent: Patients and Surrogates Perspectives on Consent for Clinical Trials in Acute Stroke and Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2019 , 8, e010905	6	12
389	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019 , 40, 2632-2653	9.5	169
388	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019 , 140, 240-261	16.7	183
387	De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 1-10	5.1	18
386	Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial. <i>Journal of the American Heart Association</i> , 2019 , 8, e011139	6	20
385	Antiplatelet Drugs in the Management of Coronary Artery Disease 2019 , 1017-1029		
384	Atrial fibrillation, with ACS and PCI: walking a tightrope. <i>European Heart Journal</i> , 2019 , 40, 1563-1566	9.5	4
383	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019 , 40, 2070-2085	9.5	35
382	Aspirin for the primary prevention of cardiovascular disease: latest evidence. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 633-643	2.5	15
381	Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1538-1549	5	16
380	Role of oral anticoagulant therapy for secondary prevention in patients with stable atherothrombotic disease manifestations. <i>Therapeutic Advances in Hematology</i> , 2019 , 10, 2040620719861475 ^{5,7}	5.7	2
379	Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. <i>Journal of the American Heart Association</i> , 2019 , 8, e013032	6	19
378	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 83-99	15.1	84
377	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1521-1537	5	189

376	Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 1171-1189	4.1	12
375	Antiplatelet Therapy Considerations in Women. <i>Cardiovascular Innovations and Applications</i> , 2019 , 3, 363-373	0.1	
374	De-escalation of oral P2Y12 inhibitors guided by platelet function testing in ACS patients undergoing PCI: impact of diabetes mellitus. <i>EuroIntervention</i> , 2019 , 15, e486-e489	3.1	
373	Aspirin-Dependent Effects on Purinergic P2Y1 Receptor Expression. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 726-734	7	4
372	Pharmacodynamics During Transition Between Platelet P2Y Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2019 , 8, 321-340	1.4	2
371	Reply: Therapeutic Window of P2Y Inhibition: Should the Current Limits Be Modified?. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 2434-2435	5	
370	Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019 , 13, 1753944719891688	3.4	4
369	Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019 , 13, 1753944719893274	3.4	28
368	Systematic Evaluation of the Robustness of the Evidence Supporting Current Guidelines on Myocardial Revascularization Using the Fragility Index. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e006017	5.8	12
367	Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 413-421	3.8	11
366	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019 , 208, 81-90	4.9	16
365	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 417-434	5	52
364	Systemic inflammatory status is associated with increased platelet reactivity in the early period after acute coronary syndromes. <i>Platelets</i> , 2018 , 29, 528-530	3.6	3
363	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005635	6	9
362	Impact of Multidrug Resistance Protein-4 Inhibitors on Modulating Platelet Function and High on-Aspirin Treatment Platelet Reactivity. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 490-501	7	7
361	Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 489-496	15.1	41
360	Cardiorenal Safety of OTC Analgesics. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 103-118	2.6	10
359	Canakinumab for secondary prevention of atherosclerotic disease. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 215-220	5.4	7

358	Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 664-674	6.1	64
357	Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 478-490	8.5	32
356	Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. <i>Journal of Translational Medicine</i> , 2018 , 16, 92	8.5	32
355	High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome - Insight from the GEPRESS study. <i>International Journal of Cardiology</i> , 2018 , 259, 20-25	3.2	12
354	Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study. <i>Circulation</i> , 2018 , 137, 2450-2462	16.7	36
353	Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 23-37	2.6	14
352	Role of genetic testing in patients undergoing percutaneous coronary intervention. <i>Expert Review of Clinical Pharmacology</i> , 2018 , 11, 151-164	3.8	39
351	The quest for safer antithrombotic treatment regimens in patients with coronary artery disease: new strategies and paradigm shifts. <i>Expert Review of Hematology</i> , 2018 , 11, 5-12	2.8	14
350	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. <i>Circulation</i> , 2018 , 138, 527-536	16.7	164
349	Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial. <i>American Heart Journal</i> , 2018 , 204, 205-209	4.9	3
348	Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1601-1610	5	17
347	Vascular access and antithrombotic therapy in patients with acute coronary syndrome. <i>Lancet, The</i> , 2018 , 392, 801-802	40	7
346	Aspirin for primary prevention of cardiovascular disease. <i>Lancet, The</i> , 2018 , 392, 988-990	40	11
345	Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study. <i>Clinical Cardiology</i> , 2018 , 41, 1004-1008	3.3	32
344	Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes. <i>Platelets</i> , 2018 , 29, 309-311	3.6	8
343	Diabetes and antiplatelet therapy: from bench to bedside. <i>Cardiovascular Diagnosis and Therapy</i> , 2018 , 8, 594-609	2.6	29
342	ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy: JACC Guideline Comparison. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 2915-2931	15.1	163
341	P2Y-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2018 , 138, 1582-1596	16.7	31

340	Gender differences on benefits and risks associated with oral antithrombotic medications for coronary artery disease. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 1041-1052	4.1	12
339	CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 997-1005	5.9	13
338	Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. <i>Blood Advances</i> , 2018 , 2, 715-730	7.8	24
337	Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y Receptor Inhibiting Therapies". <i>Circulation</i> , 2018 , 137, 2310-2311	16.7	2
336	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018 , 15, 480-496	14.8	134
335	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 190-198	2.7	12
334	Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 603-612	15.1	91
333	Reply: Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 250-251 ^{15.1}		
332	Antithrombotic therapy for patients with STEMI undergoing primary PCI. <i>Nature Reviews Cardiology</i> , 2017 , 14, 361-379	14.8	60
331	Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor. <i>American Journal of Cardiology</i> , 2017 , 119, 1135-1140	3	4
330	Tailoring duration of DAPT with risk scores. <i>Lancet, The</i> , 2017 , 389, 987-989	40	30
329	Antiplatelet Therapy After Implantation of Bioresorbable Vascular Scaffolds: A Review of the Published Data, Practical Recommendations, and Future Directions. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 425-437	5	34
328	Switching P2Y Receptor Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 67-89	1.4	8
327	Platelet-related biomarkers and their response to inhibition with aspirin and p2y-receptor antagonists in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 145-153	5.1	11
326	Reply: Collapse of the Aspirin Empire: Is it Diabetic Gastroparesis or Cardioprotective Paresis?. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2879	15.1	
325	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	20
324	Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 1861-1870	15.1	42
323	Institutional profile: University of Florida Health Personalized Medicine Program. <i>Pharmacogenomics</i> , 2017 , 18, 421-426	2.6	46

322	International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017 , 136, 1955-1975	16.7	215
321	Impact of chronic kidney disease on platelet P2Y receptor signalling in patients with type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 201-203	7	5
320	Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 44, 355-361	5.1	9
319	Dual antiplatelet therapy guided by platelet function testing. <i>Lancet, The</i> , 2017 , 390, 1718-1720	40	26
318	In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y Receptor-Mediated Signaling in Ticagrelor-Treated Patients. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1374-1375	5	7
317	Percutaneous Interventional Repair of an Intraoperative Right Coronary Artery Tear. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2464-2465	5	
316	The role of oral anticoagulant therapy in patients with acute coronary syndrome. <i>Therapeutic Advances in Hematology</i> , 2017 , 8, 353-366	5.7	13
315	Clinical Pharmacology and Cardiovascular Safety of Naproxen. <i>American Journal of Cardiovascular Drugs</i> , 2017 , 17, 97-107	4	45
314	The Rationale for and Clinical Pharmacology of Prasugrel 5 mg. <i>American Journal of Cardiovascular Drugs</i> , 2017 , 17, 109-121	4	4
313	Should endovascular approach be the first line of treatment for retroperitoneal bleeding with hemodynamic shock following percutaneous intervention? A case series. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 90, 104-111	2.7	6
312	Antiplatelet therapy and outcome in patients undergoing surgery following coronary stenting: Results of the surgery after stenting registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, E13-E25	2.7	16
311	Pretreatment with Antiplatelet Agents in the Setting of Percutaneous Coronary Intervention: When and Which Drugs?. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 13-24	1.4	1
310	Antithrombotic therapy for acute coronary syndrome: Past, present and future. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1240-1248	7	28
309	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 940-947	7	20
308	Switching P2Y12-receptor inhibitors in patients with coronary artery disease. <i>Nature Reviews Cardiology</i> , 2016 , 13, 11-27	14.8	127
307	Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 487-96	4.3	1
306	Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. <i>Circulation</i> , 2016 , 134, 780-92	16.7	66
305	Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications. <i>American Journal of Cardiovascular Drugs</i> , 2016 , 16, 391-397	4	1

304	Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease. <i>Circulation Journal</i> , 2016 , 80, 791-801	2.9	13
303	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	73
302	Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 69-77	7	14
301	Dual antiplatelet therapy after coronary stenting. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1775-874		9
300	Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 475-86	4.3	12
299	Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1089-98	5	27
298	Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1994-2004	15.1	82
297	Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 603-613	15.1	32
296	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. <i>Heart</i> , 2016 , 102, 617-25	5.1	48
295	A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. <i>European Heart Journal</i> , 2016 , 37, 2722-30	9.5	43
294	Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 1145-1154	15.1	82
293	Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 811-20	2.5	9
292	A Safety Evaluation of Cangrelor in Patients Undergoing PCI. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 275-85	4.1	11
291	Update on oral antithrombotic therapy for secondary prevention following non-ST segment elevation myocardial infarction. <i>Trends in Cardiovascular Medicine</i> , 2016 , 26, 321-34	6.9	3
290	Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2016 , 12, 312-8	3.1	22
289	Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y receptor inhibitors. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1060-7069		5
288	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. <i>Thrombosis and Haemostasis</i> , 2016 , 115, 622-31	7	21
287	Basics of Antiplatelet and Anticoagulant Therapy for Cardiovascular Disease 2016 , 377-388		

286	Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2732-2740	15.1	141
285	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016 , 182, 125-134	4.9	84
284	Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus. <i>Circulation</i> , 2016 , 134, 1579-1594	16.7	69
283	New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. <i>International Journal of Cardiology</i> , 2016 , 225, 154-158	3.2	
282	Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. <i>Nature Reviews Cardiology</i> , 2016 , 13, 609-22	14.8	17
281	Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002301	6	46
280	Cluster-randomized clinical trial examining the impact of platelet function testing on practice: the treatment with adenosine diphosphate receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome prospective open label antiplatelet therapy study. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e001712	6	10
279	Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study. <i>Circulation: Cardiovascular Interventions</i> , 2015 , 8, e002232	6	15
278	Pharmacodynamic Effects of Ticagrelor Dosing Regimens in Patients on Maintenance Ticagrelor Therapy: Results From a Prospective, Randomized, Double-Blind Investigation. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1075-1083	5	4
277	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 1762-71	9.5	218
276	Reply: elevated serum fibrinogen: an independent link between diabetes mellitus, impaired on-clopidogrel platelet inhibition, and major adverse cardiac events after percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1714-1715	15.1	1
275	A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 8-14	5.1	13
274	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 331-9	5.1	2
273	Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. <i>Circulation</i> , 2015 , 131, 1047-53	16.7	59
272	Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory. <i>Cardiovascular Revascularization Medicine</i> , 2015 , 16, 266-71	1.6	12
271	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. <i>Cardiovascular Revascularization Medicine</i> , 2015 , 16, 450-4	1.6	11
270	Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1457-1467	5	59
269	Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. <i>International Journal of Cardiology</i> , 2015 , 199, 319-25	3.2	33

268	Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike. <i>Progress in Cardiovascular Diseases</i> , 2015 , 58, 267-77	8.5	16
267	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 317-22	5.1	23
266	Drug-drug interactions between clopidogrel and novel cardiovascular drugs. <i>European Journal of Pharmacology</i> , 2015 , 765, 332-6	5.3	8
265	Percutaneous coronary intervention and atrial fibrillation: the triple therapy dilemma. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 203-8	5.1	12
264	Novel antiplatelet agents in acute coronary syndrome. <i>Nature Reviews Cardiology</i> , 2015 , 12, 30-47	14.8	230
263	Impact of bridging with perioperative low-molecular-weight heparin on cardiac and bleeding outcomes of stented patients undergoing non-cardiac surgery. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 423-31	7	16
262	Management of adjunctive antithrombotic therapy in STEMI patients treated with fibrinolysis undergoing rescue or delayed PCI. <i>Thrombosis and Haemostasis</i> , 2015 , 114, 945-57	7	1
261	Role of thromboelastography and rapid thromboelastography to assess the pharmacodynamic effects of vitamin K antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 118-25	5.1	9
260	Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2015 , 4, e002171	6	69
259	Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development. <i>Future Cardiology</i> , 2015 , 11, 547-64	1.3	13
258	Impact of impaired glucose tolerance on clopidogrel response in patients with coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 174-81	5.1	4
257	Acute coronary syndromes: applying practice guidelines and defining the unmet need in clinical practice. <i>American Journal of Cardiology</i> , 2015 , 115, 1A-2A	3	
256	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015 , 36, 1252-63	9.5	296
255	Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 131-8	5.1	10
254	Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 53-63	3.3	21
253	Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy--design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 91-100	3.3	73
252	Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 39-46	3.3	16
251	Impact of cigarette smoking on P2Y12 receptor binding activity before and after clopidogrel therapy in patients with coronary artery disease. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 47-52	3.3	5

250	Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1500-9	15.1	78
249	Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 113-24	6	54
248	Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 426-34	5	25
247	Effect of an optimized treatment with insulin on platelet reactivity after discharge in patients with an acute coronary syndrome and hyperglycemia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014 , 67, 22-7	0.7	1
246	Cangrelor 2014 , 180-192		
245	Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. <i>American Heart Journal</i> , 2014 , 168, 530-6	4.9	36
244	Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 361-8	15.1	59
243	Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1005-14	15.1	121
242	Operator radiation exposure and physical discomfort during a right versus left radial approach for coronary interventions: a randomized evaluation. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 810-6	5	27
241	Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 28, 11-22	5.1	14
240	Efecto del tratamiento optimizado con insulina en la reactividad plaquetaria tras el alta de pacientes hiperglicémicos con síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2014 , 67, 22-27	1.5	9
239	Platelet function testing in contemporary clinical and interventional practice. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2014 , 16, 300	2.1	24
238	The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. <i>Thrombosis Research</i> , 2014 , 134, 552-7	8.2	14
237	Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 311-22	7	7
236	Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014 , 111, 258-65	7	11
235	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 589-97	7	23
234	Genetic Considerations of Antiplatelet Therapy 2014 , 49-59		
233	Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 38, 127-36	5.1	12

232	Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. <i>Vascular Health and Risk Management</i> , 2014 , 10, 177-88	4.4	12
231	Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 1117-27	5	35
230	Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. <i>Current Opinion in Cardiology</i> , 2014 , 29, 553-63	2.1	8
229	Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 112-18	15.1	73
228	Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 769-77	15.1	38
227	Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 427-34	5.1	3
226	Anticoagulation Therapy. Heparins, Factor II and Factor Xa Inhibitors 2014 , 59-122		
225	Antithrombotic Issues in Women 2014 , 321-357		
224	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 81, 42-9	2.7	12
223	Platelet function profiles in patients with diabetes mellitus. <i>Journal of Cardiovascular Translational Research</i> , 2013 , 6, 329-45	3.3	31
222	Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 348-51	5.1	28
221	Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 14-7	5.1	11
220	Refining the role of antiplatelet therapy in medically managed patients with acute coronary syndrome. <i>American Journal of Cardiology</i> , 2013 , 111, 439-44	3	8
219	Long-term outcomes of patients with acute coronary syndrome and nonobstructive coronary artery disease. <i>American Journal of Cardiology</i> , 2013 , 112, 150-5	3	53
218	Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 577-83	15.1	66
217	Basics of Antithrombotic Therapy for Cardiovascular Disease: Pharmacologic Targets of Platelet Inhibitors and Anticoagulants. <i>Interventional Cardiology Clinics</i> , 2013 , 2, 499-513	1.4	1
216	Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 81, 232-42	2.7	16
215	Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013 , 344, 665-72	4.7	133

214	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2261-73	15.1	693
213	Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. <i>Circulation</i> , 2013 , 128, 2785-98	16.7	73
212	Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. <i>Circulation</i> , 2013 , 127, 673-80	16.7	58
211	Influence of HbA1c levels on platelet function profiles associated with tight glycemic control in patients presenting with hyperglycemia and an acute coronary syndrome. A subanalysis of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo"). <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 165-74	5.1	8
210	Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 35, 155-64	5.1	21
209	Platelet function and genetic testing. <i>Journal of the American College of Cardiology</i> , 2013 , 62, S21-31	15.1	23
208	Impact of prasugrel reload dosing regimens on high on-treatment platelet reactivity rates in patients on maintenance prasugrel therapy. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 182-4	5	8
207	Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013 , 7, 197-213	3.4	44
206	High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel High DOse in stable patients with residual high platelet activity) study. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, 169-79	5	18
205	The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 505-12	15.1	104
204	Effect of platelet inhibition with cangrelor during PCI on ischemic events. <i>New England Journal of Medicine</i> , 2013 , 368, 1303-13	59.2	560
203	Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. <i>American Journal of Cardiovascular Drugs</i> , 2013 , 13, 233-50	4	35
202	Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 567-74	6	39
201	Pharmacologic Options for Treatment of Ischemic Disease 2013 , 83-130		4
200	Cangrelor: a review on pharmacology and clinical trial development. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 1279-91	2.5	43
199	Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 1223-31	7	12
198	Impact of aspirin dose on adenosine diphosphate-mediated platelet activities. Results of an in vitro pilot investigation. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 777-84	7	6
197	Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 347-55	7	16

196	Clopidogrel pretreatment in primary percutaneous coronary intervention: prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 110-7	7	17
195	Antithrombotic pharmacotherapy in the elderly: general issues and clinical conundrums. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2012 , 14, 57-68	2.1	2
194	Prasugrel. <i>Advances in Cardiology</i> , 2012 , 47, 39-63		3
193	Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 297-9	5.1	7
192	Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012 , 65, 105-106	0.7	1
191	Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 2032-40	15.1	68
190	Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. <i>Circulation</i> , 2012 , 125, 978-86	16.7	139
189	Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. <i>Revista Espanola De Cardiologia</i> , 2012 , 65, 105-6	1.5	9
188	The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. <i>Drugs</i> , 2012 , 72, 2087-116	12.1	85
187	New directions in antiplatelet therapy. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 433-45	6	52
186	Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 891-900	15.1	50
185	Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1928-37	15.1	108
184	Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1681-7	15.1	16
183	A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement in Clopidogrel-Treated Coronary Arteries) Trial. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1681-7	15.1	484
182	Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 2338-43	15.1	91
181	Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. <i>JACC: Cardiovascular Interventions</i> , 2012 , 5, 293-300	5	38
180	Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 347-56	6	25
179	Effects of pioglitazone on platelet P2Y ₁₂ -mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 930-6	7	13

178	Antithrombotic therapy in patients with chronic kidney disease. <i>Circulation</i> , 2012 , 125, 2649-61	16.7	92
177	Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2012 , 80, 395-405	2.7	9
176	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 44-55	5.1	113
175	Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 36-43	5.1	14
174	Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 265-74	27.4	329
173	Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease. <i>Future Cardiology</i> , 2012 , 8, 503-11	1.3	5
172	Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease. <i>Platelets</i> , 2012 , 23, 537-51	3.6	16
171	A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. <i>Circulation: Cardiovascular Interventions</i> , 2012 , 5, 336-46	6	66
170	Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. <i>Current Pharmaceutical Design</i> , 2012 , 18, 5273-93	3.3	10
169	Antithrombotic pharmacotherapy in patients with established coronary artery disease 2012 , 287-301		
168	Antithrombotic pharmacotherapy in patients with established coronary artery disease 2012 , 287-301		
167	Clopidogrel-drug interactions. <i>Journal of the American College of Cardiology</i> , 2011 , 57, 1251-63	15.1	154
166	Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 30-9	15.1	44
165	Impact of gastric acid-suppressing therapies on platelet reactivity in patients with coronary artery disease treated with clopidogrel: results of a pharmacodynamic study. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1396-8	15.1	8
164	Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2011 , 4, 905-12	5	16
163	Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 572-84	7	152
162	Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2011 , 150, 325-31	3.2	119
161	Current concepts on coronary revascularization in diabetic patients. <i>European Heart Journal</i> , 2011 , 32, 2748-57	9.5	67

160	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes Mellitus (OPTIMUS)-3 Trial. <i>European Heart Journal</i> , 2011 , 32, 838-46	9.5	161
159	Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. <i>Future Cardiology</i> , 2011 , 7, 381-402	10	
158	Functional profile of the platelet P2Y ₁₂ receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 730-2	7	34
157	Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 1149-57	7	26
156	Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 67-74	7	33
155	Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. <i>Thrombosis and Haemostasis</i> , 2011 , 106, 253-62	7	32
154	Antiplatelet therapy: thrombin receptor antagonists. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 658-71	3.8	25
153	Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 65-74	6.1	217
152	¿Los nuevos antagonistas del receptor P2Y ₁₂ pueden reemplazar a los inhibidores de la glucoproteína IIb/IIIa?. <i>Revista Espanola De Cardiologia Suplementos</i> , 2011 , 11, 14-19	0.2	
151	Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B ₂ inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. <i>Clinical Therapeutics</i> , 2011 , 33, 1883-93	3.5	14
150	Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. <i>American Journal of Cardiology</i> , 2011 , 107, 186-94	3	100
149	Can resistance to aspirin be reversed after an additional dose?. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 356-61	5.1	10
148	Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 119-33	5.9	11
147	Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y ₁₂ assay: Impact on Thrombosis and Safety (GRAVITAS) trial. <i>Circulation</i> , 2011 , 124, 1132-7	16.7	331
146	Unravelling the benefit against the risk of long-term dual antiplatelet therapy. <i>Current Opinion in Cardiology</i> , 2011 , 26 Suppl 1, S22-30	2.1	3
145	Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 273-9	6	31
144	Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2221-8	27.4	268
143	Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1097-105	27.4	959

142	Randomized trial of atropaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin. <i>Coronary Artery Disease Trial. Circulation</i> , 2011 , 123, 1854-63	16.7	112
141	Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 180-7	6	151
140	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 522-34	6	88
139	Safety and tolerability of atropaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin. <i>Acute Coronary Syndromes Trial. Circulation</i> , 2011 , 123, 1843-53	16.7	130
138	Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. <i>Circulation</i> , 2011 , 124, 544-54	16.7	329
137	Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 697-710	2.5	9
136	Diabetes and antiplatelet therapy in acute coronary syndrome. <i>Circulation</i> , 2011 , 123, 798-813	16.7	229
135	Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Síndrome Coronario Agudo"). <i>Heart</i> , 2011 , 97, 803-9	5.1	17
134	Impact of race and gender on antithrombotic therapy. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 471-84	7	55
133	Platelet function testing and risk of bleeding complications. <i>Thrombosis and Haemostasis</i> , 2010 , 103, 1128-35	7	79
132	Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study. <i>Circulation: Cardiovascular Interventions</i> , 2010 , 3, 436-41	6	47
131	Platelet abnormalities in diabetes mellitus. <i>Diabetes and Vascular Disease Research</i> , 2010 , 7, 251-9	3.3	138
130	Platelet thrombin receptor antagonism and atherothrombosis. <i>European Heart Journal</i> , 2010 , 31, 17-28	9.5	183
129	Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease. <i>Diabetes and Vascular Disease Research</i> , 2010 , 7, 274-88	3.3	5
128	Update on the clinical development of cangrelor. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 1069-73	7.7	19
127	Elinogrel: pharmacological principles, preclinical and early phase clinical testing. <i>Future Cardiology</i> , 2010 , 6, 445-53	1.3	47
126	Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 1557-67	5.9	8
125	Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 1139-46	15.1	169

124	Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1017-23	15.1	148
123	Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATElet inhibition and patient Outcomes) PLATELET substudy. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1456-62	15.1	287
122	Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 919-33	15.1	913
121	Antithrombotic therapy in the elderly. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1683-92	15.1	98
120	Platelet adenosine diphosphate P2Y ₁₂ receptor antagonism: benefits and limitations of current treatment strategies and future directions. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010 , 63, 60-76 ^{0.7}		17
119	Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATElet inhibition and patient Outcomes (PLATO) trial. <i>European Heart Journal</i> , 2010 , 31, 3006-16	9.5	317
118	Use of Impella Recover LP 2.5 in elective high risk percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2010 , 145, 235-237	3.2	19
117	Inhibici3n del receptor plaquetario P2Y ₁₂ de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terap3uticas actuales y perspectivas futuras. <i>Revista Espanola De Cardiologia</i> , 2010 , 63, 60-76	1.5	58
116	Platelet P2Y ₁₂ receptor inhibition: an update on clinical drug development. <i>American Journal of Cardiovascular Drugs</i> , 2010 , 10, 217-26	4	18
115	Investigations on 5-HT _{2A} receptor expression and effects of tegaserod on human platelet aggregation in vitro. <i>American Journal of Therapeutics</i> , 2010 , 17, 543-52	1	17
114	Basic principles of platelet biology and clinical implications. <i>Circulation Journal</i> , 2010 , 74, 597-607	2.9	200
113	Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y ₁₂ receptor antagonist. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 151-8	2.5	64
112	Mechanism of action and clinical development of platelet thrombin receptor antagonists. <i>Expert Review of Cardiovascular Therapy</i> , 2010 , 8, 1191-200	2.5	18
111	Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes. <i>Trends in Cardiovascular Medicine</i> , 2010 , 20, 211-7	6.9	2
110	Diabetes mellitus: the scary killer haunting silently. <i>EuroIntervention</i> , 2010 , 5, 879-881	3.1	3
109	Different apparent prognostic value of hsCRP in type 2 diabetic and nondiabetic patients with acute coronary syndromes. <i>Clinical Chemistry</i> , 2009 , 55, 365-8	5.5	25
108	Platelet inhibition with cangrelor in patients undergoing PCI. <i>New England Journal of Medicine</i> , 2009 , 361, 2318-29	59.2	454
107	Vessel shrinkage as a sign of atherosclerosis progression in type 2 diabetes: a serial intravascular ultrasound analysis. <i>Diabetes</i> , 2009 , 58, 209-14	0.9	33

106	Assessment of microcirculatory remodeling with intracoronary flow velocity and pressure measurements: validation with endomyocardial sampling in cardiac allografts. <i>Circulation</i> , 2009 , 120, 1561-8	16.7	68
105	Emerging insights on antiplatelet therapy. Introduction. <i>American Journal of Cardiology</i> , 2009 , 103, 1A-3A		1
104	Variability in responsiveness to oral antiplatelet therapy. <i>American Journal of Cardiology</i> , 2009 , 103, 27A-34A		118
103	Advances in antiplatelet therapy: agents in clinical development. <i>American Journal of Cardiology</i> , 2009 , 103, 40A-51A	3	75
102	Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. <i>Catheterization and Cardiovascular Interventions</i> , 2009 , 73, 1-14	2.7	28
101	Strategies for drug-eluting stent treatment of bifurcation coronary artery disease in the United States: insights from the e-Cypher S.T.L.R.trial. <i>Catheterization and Cardiovascular Interventions</i> , 2009 , 73, 890-7	2.7	5
100	Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2009 , 73, 291-8	2.7	19
99	Contemporary issues on clopidogrel therapy: a critical appraisal. <i>Internal and Emergency Medicine</i> , 2009 , 4, 195-8	3.7	2
98	Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 1279-85	5	29
97	Clopidogrel response variability: current status and future directions. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 7-14	7	91
96	Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study. <i>Circulation</i> , 2009 , 119, 3215-22	16.7	191
95	Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. <i>Thrombosis Research</i> , 2009 , 124, 318-22	8.2	33
94	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009 , 157, 818-24, 824.e1	4.9	92
93	Pharmacogenetics in cardiovascular antithrombotic therapy. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1041-57	15.1	81
92	Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 361-9	2.5	11
91	Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009 , 23, 375-88	6.5	43
90	Cangrelor: a review on its mechanism of action and clinical development. <i>Expert Review of Cardiovascular Therapy</i> , 2009 , 7, 1195-201	2.5	71
89	Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. <i>European Heart Journal</i> , 2009 , 30, 1753-63	9.5	206

88	Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. <i>Vascular Health and Risk Management</i> , 2009 , 5, 101-19	4.4	11
87	New antiplatelet agents. <i>Clinical Advances in Hematology and Oncology</i> , 2009 , 7, 584-7	0.6	
86	Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. <i>American Journal of Cardiology</i> , 2008 , 101, 440-5	3	64
85	Aspirin desensitization in patients undergoing percutaneous coronary interventions with stent implantation. <i>American Journal of Cardiology</i> , 2008 , 101, 786-9	3	61
84	Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). <i>American Journal of Cardiology</i> , 2008 , 101, 1704-11	3	178
83	Prognostic significance of troponin T elevation in patients without chest pain. <i>American Journal of Cardiology</i> , 2008 , 102, 668-71	3	4
82	Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. <i>American Journal of Cardiology</i> , 2008 , 102, 1618-23	3	137
81	Variable histological and ultrasonic characteristics of restenosis after drug-eluting stents. <i>International Journal of Cardiology</i> , 2008 , 130, 444-8	3.2	14
80	Platelet inhibitor therapy: current perspectives and emerging novel agents: introduction. <i>American Heart Journal</i> , 2008 , 156, S1-2	4.9	1
79	Current antiplatelet therapies: benefits and limitations. <i>American Heart Journal</i> , 2008 , 156, S3-9	4.9	40
78	Pharmacology of emerging novel platelet inhibitors. <i>American Heart Journal</i> , 2008 , 156, S10-5	4.9	74
77	Clinical profile of prasugrel, a novel thienopyridine. <i>American Heart Journal</i> , 2008 , 156, S16-22	4.9	37
76	Clinical overview of promising nonthienopyridine antiplatelet agents. <i>American Heart Journal</i> , 2008 , 156, S23-8	4.9	33
75	Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. <i>Circulation</i> , 2008 , 118, 1626-36	16.7	586
74	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. <i>European Heart Journal</i> , 2008 , 29, 2202-11	9.5	161
73	Hypertriglyceridemia and ischemic stroke. <i>European Neurology</i> , 2008 , 60, 269-78	2.1	28
72	A systematic review of outcomes in patients with staged carotid artery stenting and coronary artery bypass graft surgery. <i>Stroke</i> , 2008 , 39, 361-5	6.7	42
71	Prasugrel: a novel platelet ADP P2Y ₁₂ receptor antagonist. A review on its mechanism of action and clinical development. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2893-900	4	31

70	Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. <i>Thrombosis and Haemostasis</i> , 2008 , 99, 161-8	7	66
69	Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus. <i>International Journal of Cardiovascular Imaging</i> , 2008 , 24, 125-32	2.5	5
68	Diagnostic accuracy of quantitative cardiac MRI evaluation compared to stress single-photon-emission computed tomography. <i>International Journal of Cardiovascular Imaging</i> , 2008 , 24, 293-9	2.5	6
67	Assessment of potential relationship between wall shear stress and arterial wall response after bare metal stent and sirolimus-eluting stent implantation in patients with diabetes mellitus. <i>International Journal of Cardiovascular Imaging</i> , 2008 , 24, 357-64	2.5	16
66	Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol design. <i>Cardiovascular Drugs and Therapy</i> , 2008 , 22, 313-20	3.9	17
65	Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2008 , 72, 448-56	2.7	52
64	Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2008 , 31, 128-35	3.3	1
63	Investigating the mechanisms of hyporesponse to antiplatelet approaches. <i>Clinical Cardiology</i> , 2008 , 31, 121-7	3.3	7
62	Assessing the current role of platelet function testing. <i>Clinical Cardiology</i> , 2008 , 31, 110-6	3.3	24
61	The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. <i>Clinical Cardiology</i> , 2008 , 31, 117-20	3.3	27
60	Short- or long-term outcomes of coronary artery aneurysms occurring after directional coronary atherectomy. <i>Journal of Invasive Cardiology</i> , 2008 , 20, 159-60	0.7	3
59	Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. <i>Circulation</i> , 2007 , 115, 708-16	16.7	384
58	Quantitative magnetic resonance perfusion imaging detects anatomic and physiologic coronary artery disease as measured by coronary angiography and fractional flow reserve. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 514-22	15.1	125
57	Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 1541-7	15.1	286
56	Intravascular ultrasound findings during episodes of drug-eluting stent thrombosis. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2095-7	15.1	78
55	Platelet function testing and cardiovascular outcomes: Steps forward in identifying the best predictive measure. <i>Thrombosis and Haemostasis</i> , 2007 , 98, 707-709	7	24
54	Relocation of minimal luminal diameter after bare metal and drug-eluting stent implantation: incidence and impact on angiographic late loss. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 69, 181-8	2.7	17
53	Heterogeneity of atherosclerotic plaque characteristics in human coronary artery disease: a three-dimensional intravascular ultrasound study. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 70, 349-56	2.7	23

52	Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. <i>BMC Medical Genetics</i> , 2007 , 8, 59	2.1	46
51	The impact of previously occluded noninfarct vessels in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2007 , 99, 429-30	3	
50	Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2007 , 100, 1199-206	3	96
49	Quantitative contrast enhanced magnetic resonance imaging for the evaluation of peripheral arterial disease: a comparative study versus standard digital angiography. <i>International Journal of Cardiovascular Imaging</i> , 2007 , 23, 225-32	2.5	9
48	Clinical impact of in-stent late loss after drug-eluting coronary stent implantation. <i>European Heart Journal</i> , 2007 , 28, 1583-91	9.5	44
47	Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. <i>Circulation</i> , 2007 , 116, 2333-42	16.7	718
46	Antiplatelet therapy in type 2 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007 , 14, 124-31	4	34
45	Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. <i>European Heart Journal</i> , 2007 , 28, 1946-52	9.5	60
44	Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: hitting the TARGET in the TENACITY trial?. <i>Thrombosis Research</i> , 2007 , 119, 175-81	8.2	6
43	Evaluation of cardiac magnetic resonance imaging parameters to detect anatomically and hemodynamically significant coronary artery disease. <i>American Heart Journal</i> , 2007 , 154, 298-305	4.9	34
42	Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1505-16	15.1	769
41	ADP receptor antagonism: what's in the pipeline?. <i>American Journal of Cardiovascular Drugs</i> , 2007 , 7, 423-32	4	43
40	Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2006 , 97, 38-43	3	100
39	Intravascular ultrasound characterization of the "black hole" phenomenon after drug-eluting stent implantation. <i>American Journal of Cardiology</i> , 2006 , 97, 203-6	3	22
38	Influence of the CD14 C260T promoter polymorphism on C-reactive protein levels in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 2006 , 98, 1182-4	3	10
37	Antiagregaci3n oral e intervencionismo coronario percut3neo. <i>Revista Espanola De Cardiologia Suplementos</i> , 2006 , 6, 49H-56H	0.2	
36	"Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study". <i>Catheterization and Cardiovascular Interventions</i> , 2006 , 67, 846-51	2.7	21
35	Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. <i>Diabetes</i> , 2006 , 55, 780-4	0.9	127

34	Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery disease. <i>Platelets</i> , 2006 , 17, 586-90	3.6	25
33	Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006 , 26, 1895-900	9.4	190
32	Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 2172-9	15.1	79
31	Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 298-304	15.1	243
30	Characterization of plaque prolapse after drug-eluting stent implantation in diabetic patients: a three-dimensional volumetric intravascular ultrasound outcome study. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 1139-45	15.1	46
29	Clopidogrel for up to one year after PCI is cost-effective for people with acute coronary syndromes. <i>Evidence-based Cardiovascular Medicine</i> , 2006 , 10, 116-8		1
28	Tackling the diabetic platelet: is high clopidogrel dosing the answer?. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 2563-5	15.4	5
27	Prognostic impact of a chronic occlusion in a noninfarct vessel in patients with acute myocardial infarction and multivessel disease undergoing primary percutaneous coronary intervention. <i>Journal of Invasive Cardiology</i> , 2006 , 18, 16-9	0.7	42
26	LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. <i>European Heart Journal</i> , 2005 , 26, 2307-12	9.5	24
25	Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. <i>Thrombosis Research</i> , 2005 , 115, 101-8	8.2	138
24	Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. <i>Thrombosis Research</i> , 2005 , 116, 491-7	8.2	124
23	Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 954-9	15.1	437
22	Raising the loading dose of clopidogrel: aiming at the proper target?: reply. <i>European Heart Journal</i> , 2005 , 26, 740-741	9.5	
21	Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. <i>American Journal of Cardiology</i> , 2005 , 96, 1095-9	3	51
20	Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. <i>Diabetes</i> , 2005 , 54, 2430-5	0.9	423
19	Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. <i>Circulation</i> , 2005 , 112, 2175-83	16.7	295
18	Long-term outcome of patients with proximal left anterior descending coronary artery in-stent restenosis treated with a second percutaneous procedure. <i>Journal of Invasive Cardiology</i> , 2005 , 17, 218-21	0.7	1
17	Sirolimus-eluting stents for treatment of complex bypass graft disease: insights from the SECURE registry. <i>Journal of Invasive Cardiology</i> , 2005 , 17, 396-8	0.7	10

16	High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. <i>European Heart Journal</i> , 2004 , 25, 1903-10	9.5	230
15	Imaging of atherosclerotic plaque. <i>International Journal of Cardiovascular Imaging</i> , 2004 , 20, 553-9	2.5	8
14	Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 62, 39-42	2.7	5
13	"Candy wrapper" effect after drug-eluting stent implantation: did you or stumbling over the same stone again?. <i>Catheterization and Cardiovascular Interventions</i> , 2004 , 61, 387-91	2.7	24
12	La inflamaci3n en los s3ndromes coronarios agudos: mecanismos e implicaciones cl3nicas. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 433-446	1.5	19
11	Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 1964-72	15.1	72
10	Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: results of a randomized intravascular ultrasound study. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 520-7	15.1	22
9	807 C/T Polymorphism of the glycoprotein Ia gene and pharmacogenetic modulation of platelet response to dual antiplatelet treatment. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 427-33	1	41
8	PIA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. <i>Blood Coagulation and Fibrinolysis</i> , 2004 , 15, 89-93	1	72
7	Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted?. <i>Journal of Invasive Cardiology</i> , 2004 , 16, 169-74	0.7	138
6	Extensive thrombus of distal anastomosis of saphenous vein graft. <i>Journal of Invasive Cardiology</i> , 2004 , 16, 198-200	0.7	
5	Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study. <i>Journal of Invasive Cardiology</i> , 2004 , 16, 325-9	0.7	20
4	Intracoronary brachytherapy following drug-eluting stent failure. It's still not time to hang up the spikes!. <i>Cardiovascular Radiation Medicine</i> , 2003 , 4, 171-5		7
3	Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. <i>Circulation</i> , 2003 , 107, 3015-7	16.7	61
2	Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein. <i>Circulation</i> , 2002 , 105, 800-3	16.7	111
1	Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. <i>Circulation</i> , 2001 , 103, 2236-41	16.7	82